Tag Archives: Urogen Pharma Ltd

H.C. Wainwright Thinks Urogen Pharma Ltd’s Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma Ltd (URGN – Research Report) today and set a price target of $75. The company’s shares closed yesterday at $38.48, close to its 52-week low of $36.95. According

Analysts Offer Insights on Healthcare Companies: Urogen Pharma Ltd (NASDAQ: URGN) and BeiGene Ltd (NASDAQ: BGNE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Urogen Pharma Ltd (URGN – Research Report) and BeiGene Ltd (BGNE – Research Report) with bullish sentiments. Urogen Pharma Ltd (URGN) In

Urogen Pharma Ltd (URGN) Receives a Buy from Oppenheimer

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Urogen Pharma Ltd (URGN – Research Report), with a price target of $75. The company’s shares closed yesterday at $51.35. Gershell noted: “Significant update from UGN-101’s

Cowen & Co. Keeps Their Buy Rating on Urogen Pharma Ltd (URGN)

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Urogen Pharma Ltd (NASDAQ: URGN). The company’s shares opened today at $46. According to TipRanks.com, Peaker is a 5-star analyst with an average return

Cowen & Co. Believes Urogen Pharma Ltd (NASDAQ: URGN) Still Has Room to Grow

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Urogen Pharma Ltd (NASDAQ: URGN). The company’s shares opened today at $60.14, close to its 52-week high of $66.38. According to TipRanks.com, Peaker is

Urogen Pharma Ltd Received its Third Buy in a Row

After Oppenheimer and Ladenburg assigned a Buy rating to Urogen Pharma Ltd in the last month, the company received another Buy, this time from Cowen & Co.. Analyst Boris Peaker maintained a Buy rating on Urogen Pharma Ltd (NASDAQ: URGN)